Commercial Probiotic Products: A Call for Improved Quality Control. A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics

Sanja Kolaček, Iva Hojsak, Roberto Berni Canani, Alfredo Guarino, Flavia Indrio, Rok Orel, Bruno Pot, Raanan Shamir, Hania Szajewska, Yvan Vandenplas, Johannes Van Goudoever, Zvi Weizman

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Probiotics have been proposed for a number of indications ranging from the hypothetical long-term immunomodulatory effects to proven benefits in the management of different clinical conditions. An increasing number of commercial products containing probiotics are available. In those products, irrespective if it is food, food supplement, medical food, or drug, the probiotic microorganisms have to be present in a sufficient number by the end of the shelf-life, to pass through the gastrointestinal tract resisting acid and bile, to colonize the gut, and to retain functional properties required to obtain the suggested beneficial effect. Finally, it should be contamination-free. Studies organized worldwide and summarized in this article have shown that inconsistencies and deviations from the information provided on the product label are surprisingly common. Frequently strains are misidentified and misclassified, products are occasionally contaminated, sometimes with even facultative or obligatory pathogens, strains are not viable, the labeled number of colonies cannot be verified, or the functional properties are diminished to the extent that preclude the proposed health benefit. As the probiotic preparations are commonly used for a wide range of conditions, the aim of the Working Group was to summarize results of the studies looking into the quality of the probiotic products and to raise the awareness of the important issue of their quality control. Based on the results obtained, we strongly suggest a more stringent quality control process. This process should ensure that the probiotic content as mentioned on the label meets the actual content throughout the shelf life of the product, while no contamination is present.

Original languageEnglish
Pages (from-to)117-124
Number of pages8
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume65
Issue number1
DOIs
Publication statusPublished - 1 Jul 2017

Cite this

Kolaček, Sanja ; Hojsak, Iva ; Berni Canani, Roberto ; Guarino, Alfredo ; Indrio, Flavia ; Orel, Rok ; Pot, Bruno ; Shamir, Raanan ; Szajewska, Hania ; Vandenplas, Yvan ; Van Goudoever, Johannes ; Weizman, Zvi. / Commercial Probiotic Products : A Call for Improved Quality Control. A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics. In: Journal of Pediatric Gastroenterology and Nutrition. 2017 ; Vol. 65, No. 1. pp. 117-124.
@article{f21af0e925be44b88384b7e313dcc497,
title = "Commercial Probiotic Products: A Call for Improved Quality Control. A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics",
abstract = "Probiotics have been proposed for a number of indications ranging from the hypothetical long-term immunomodulatory effects to proven benefits in the management of different clinical conditions. An increasing number of commercial products containing probiotics are available. In those products, irrespective if it is food, food supplement, medical food, or drug, the probiotic microorganisms have to be present in a sufficient number by the end of the shelf-life, to pass through the gastrointestinal tract resisting acid and bile, to colonize the gut, and to retain functional properties required to obtain the suggested beneficial effect. Finally, it should be contamination-free. Studies organized worldwide and summarized in this article have shown that inconsistencies and deviations from the information provided on the product label are surprisingly common. Frequently strains are misidentified and misclassified, products are occasionally contaminated, sometimes with even facultative or obligatory pathogens, strains are not viable, the labeled number of colonies cannot be verified, or the functional properties are diminished to the extent that preclude the proposed health benefit. As the probiotic preparations are commonly used for a wide range of conditions, the aim of the Working Group was to summarize results of the studies looking into the quality of the probiotic products and to raise the awareness of the important issue of their quality control. Based on the results obtained, we strongly suggest a more stringent quality control process. This process should ensure that the probiotic content as mentioned on the label meets the actual content throughout the shelf life of the product, while no contamination is present.",
keywords = "children, commercial products, food supplement, probiotics, quality control, regulation",
author = "Sanja Kolaček and Iva Hojsak and {Berni Canani}, Roberto and Alfredo Guarino and Flavia Indrio and Rok Orel and Bruno Pot and Raanan Shamir and Hania Szajewska and Yvan Vandenplas and {Van Goudoever}, Johannes and Zvi Weizman",
year = "2017",
month = "7",
day = "1",
doi = "10.1097/MPG.0000000000001603",
language = "English",
volume = "65",
pages = "117--124",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Kolaček, S, Hojsak, I, Berni Canani, R, Guarino, A, Indrio, F, Orel, R, Pot, B, Shamir, R, Szajewska, H, Vandenplas, Y, Van Goudoever, J & Weizman, Z 2017, 'Commercial Probiotic Products: A Call for Improved Quality Control. A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics' Journal of Pediatric Gastroenterology and Nutrition, vol. 65, no. 1, pp. 117-124. https://doi.org/10.1097/MPG.0000000000001603

Commercial Probiotic Products : A Call for Improved Quality Control. A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics. / Kolaček, Sanja; Hojsak, Iva; Berni Canani, Roberto; Guarino, Alfredo; Indrio, Flavia; Orel, Rok; Pot, Bruno; Shamir, Raanan; Szajewska, Hania; Vandenplas, Yvan; Van Goudoever, Johannes; Weizman, Zvi.

In: Journal of Pediatric Gastroenterology and Nutrition, Vol. 65, No. 1, 01.07.2017, p. 117-124.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Commercial Probiotic Products

T2 - A Call for Improved Quality Control. A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics

AU - Kolaček, Sanja

AU - Hojsak, Iva

AU - Berni Canani, Roberto

AU - Guarino, Alfredo

AU - Indrio, Flavia

AU - Orel, Rok

AU - Pot, Bruno

AU - Shamir, Raanan

AU - Szajewska, Hania

AU - Vandenplas, Yvan

AU - Van Goudoever, Johannes

AU - Weizman, Zvi

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Probiotics have been proposed for a number of indications ranging from the hypothetical long-term immunomodulatory effects to proven benefits in the management of different clinical conditions. An increasing number of commercial products containing probiotics are available. In those products, irrespective if it is food, food supplement, medical food, or drug, the probiotic microorganisms have to be present in a sufficient number by the end of the shelf-life, to pass through the gastrointestinal tract resisting acid and bile, to colonize the gut, and to retain functional properties required to obtain the suggested beneficial effect. Finally, it should be contamination-free. Studies organized worldwide and summarized in this article have shown that inconsistencies and deviations from the information provided on the product label are surprisingly common. Frequently strains are misidentified and misclassified, products are occasionally contaminated, sometimes with even facultative or obligatory pathogens, strains are not viable, the labeled number of colonies cannot be verified, or the functional properties are diminished to the extent that preclude the proposed health benefit. As the probiotic preparations are commonly used for a wide range of conditions, the aim of the Working Group was to summarize results of the studies looking into the quality of the probiotic products and to raise the awareness of the important issue of their quality control. Based on the results obtained, we strongly suggest a more stringent quality control process. This process should ensure that the probiotic content as mentioned on the label meets the actual content throughout the shelf life of the product, while no contamination is present.

AB - Probiotics have been proposed for a number of indications ranging from the hypothetical long-term immunomodulatory effects to proven benefits in the management of different clinical conditions. An increasing number of commercial products containing probiotics are available. In those products, irrespective if it is food, food supplement, medical food, or drug, the probiotic microorganisms have to be present in a sufficient number by the end of the shelf-life, to pass through the gastrointestinal tract resisting acid and bile, to colonize the gut, and to retain functional properties required to obtain the suggested beneficial effect. Finally, it should be contamination-free. Studies organized worldwide and summarized in this article have shown that inconsistencies and deviations from the information provided on the product label are surprisingly common. Frequently strains are misidentified and misclassified, products are occasionally contaminated, sometimes with even facultative or obligatory pathogens, strains are not viable, the labeled number of colonies cannot be verified, or the functional properties are diminished to the extent that preclude the proposed health benefit. As the probiotic preparations are commonly used for a wide range of conditions, the aim of the Working Group was to summarize results of the studies looking into the quality of the probiotic products and to raise the awareness of the important issue of their quality control. Based on the results obtained, we strongly suggest a more stringent quality control process. This process should ensure that the probiotic content as mentioned on the label meets the actual content throughout the shelf life of the product, while no contamination is present.

KW - children

KW - commercial products

KW - food supplement

KW - probiotics

KW - quality control

KW - regulation

UR - http://www.scopus.com/inward/record.url?scp=85017454544&partnerID=8YFLogxK

U2 - 10.1097/MPG.0000000000001603

DO - 10.1097/MPG.0000000000001603

M3 - Review article

VL - 65

SP - 117

EP - 124

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 1

ER -